NO308610B1 - Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer - Google Patents

Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer Download PDF

Info

Publication number: NO308610B1
Authority: NO; Norway
Prior art keywords: rna; sequence; ribozyme; compound; stated
Prior art date: 1987-12-15

Application number

NO902661A

Other languages

English (en)

Norwegian (no)

Other versions

NO902661L (no

NO902661D0 (no

Inventor

James Phillip Haseloff

Wayne Lyle Gerlach

Philip Anthony Jennings

Fiona Helen Cameron

Original Assignee

Gene Shears Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-15

Filing date

1990-06-14

Publication date

2000-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27507391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308610(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-06-14 Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd

1990-06-14 Publication of NO902661D0 publication Critical patent/NO902661D0/no

1990-08-14 Publication of NO902661L publication Critical patent/NO902661L/no

2000-10-02 Publication of NO308610B1 publication Critical patent/NO308610B1/no

Links

108091092562 ribozyme Proteins 0.000 title claims description 202
108090000994 Catalytic RNA Proteins 0.000 title claims description 196
102000053642 Catalytic RNA Human genes 0.000 title claims description 194
238000000034 method Methods 0.000 title claims description 32
238000002360 preparation method Methods 0.000 title claims description 10
238000011282 treatment Methods 0.000 title description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 168
239000002773 nucleotide Substances 0.000 claims description 51
125000003729 nucleotide group Chemical group 0.000 claims description 46
108091028664 Ribonucleotide Proteins 0.000 claims description 41
239000002336 ribonucleotide Substances 0.000 claims description 41
125000002652 ribonucleotide group Chemical group 0.000 claims description 41
210000004027 cell Anatomy 0.000 claims description 39
150000001875 compounds Chemical class 0.000 claims description 33
108090000623 proteins and genes Proteins 0.000 claims description 29
108020004414 DNA Proteins 0.000 claims description 26
239000013598 vector Substances 0.000 claims description 25
238000012546 transfer Methods 0.000 claims description 22
239000000126 substance Substances 0.000 claims description 18
238000013518 transcription Methods 0.000 claims description 15
230000035897 transcription Effects 0.000 claims description 15
108091034117 Oligonucleotide Proteins 0.000 claims description 13
108091027075 5S-rRNA precursor Proteins 0.000 claims description 12
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 10
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 10
230000000415 inactivating effect Effects 0.000 claims description 10
210000003527 eukaryotic cell Anatomy 0.000 claims description 6
210000001236 prokaryotic cell Anatomy 0.000 claims description 6
108020000999 Viral RNA Proteins 0.000 claims description 4
210000004102 animal cell Anatomy 0.000 claims description 4
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 61
238000005520 cutting process Methods 0.000 description 61
230000000694 effects Effects 0.000 description 53
239000013612 plasmid Substances 0.000 description 43
230000003197 catalytic effect Effects 0.000 description 36
239000012634 fragment Substances 0.000 description 32
238000003776 cleavage reaction Methods 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 21
239000000758 substrate Substances 0.000 description 20
241000196324 Embryophyta Species 0.000 description 19
238000002474 experimental method Methods 0.000 description 19
238000000338 in vitro Methods 0.000 description 18
230000007017 scission Effects 0.000 description 18
241000726311 Citrus exocortis viroid Species 0.000 description 17
101150055766 cat gene Proteins 0.000 description 17
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 17
238000001727 in vivo Methods 0.000 description 15
239000000047 product Substances 0.000 description 14
230000000692 anti-sense effect Effects 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
108010093099 Endoribonucleases Proteins 0.000 description 10
108060001084 Luciferase Proteins 0.000 description 10
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
102100030011 Endoribonuclease Human genes 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
239000003184 complementary RNA Substances 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 7
239000005089 Luciferase Substances 0.000 description 7
238000010276 construction Methods 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
108020005544 Antisense RNA Proteins 0.000 description 6
108020005543 Satellite RNA Proteins 0.000 description 6
241001428638 Tobacco ringspot virus satellite RNA Species 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
108020001778 catalytic domains Proteins 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
241000724705 Lucerne transient streak virus Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
101710137500 T7 RNA polymerase Proteins 0.000 description 5
239000000499 gel Substances 0.000 description 5
238000001502 gel electrophoresis Methods 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
210000001938 protoplast Anatomy 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
241000726301 Avocado sunblotch viroid Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
241000724703 Subterranean clover mottle virus Species 0.000 description 4
238000000246 agarose gel electrophoresis Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
229960005091 chloramphenicol Drugs 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
229940035893 uracil Drugs 0.000 description 4
241000701489 Cauliflower mosaic virus Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
108010065868 RNA polymerase SP6 Proteins 0.000 description 3
241000724704 Solanum nodiflorum mottle virus Species 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101100268665 Caenorhabditis elegans acc-1 gene Proteins 0.000 description 2
101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 2
241000269333 Caudata Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
108020004394 Complementary RNA Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
241001452028 Escherichia coli DH1 Species 0.000 description 2
208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 2
241000208125 Nicotiana Species 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 2
108020004487 Satellite DNA Proteins 0.000 description 2
241000723677 Tobacco ringspot virus Species 0.000 description 2
241000724701 Velvet tobacco mottle virus Species 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
241000726445 Viroids Species 0.000 description 2
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
230000002358 autolytic effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
230000010310 bacterial transformation Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
108091036078 conserved sequence Proteins 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
229940015043 glyoxal Drugs 0.000 description 2
208000016861 hereditary angioedema type 3 Diseases 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000009630 liquid culture Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
230000002245 ribonucleolytic effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000001890 transfection Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
GGKNTGJPGZQNID-UHFFFAOYSA-N (1-$l^{1}-oxidanyl-2,2,6,6-tetramethylpiperidin-4-yl)-trimethylazanium Chemical compound CC1(C)CC([N+](C)(C)C)CC(C)(C)N1[O] GGKNTGJPGZQNID-UHFFFAOYSA-N 0.000 description 1
102100039601 ARF GTPase-activating protein GIT1 Human genes 0.000 description 1
101710194905 ARF GTPase-activating protein GIT1 Proteins 0.000 description 1
102100039602 ARF GTPase-activating protein GIT2 Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000589155 Agrobacterium tumefaciens Species 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000207199 Citrus Species 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241000208133 Nicotiana plumbaginifolia Species 0.000 description 1
241000228669 Nicotiana velutina Species 0.000 description 1
108700001094 Plant Genes Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
108010046983 Ribonuclease T1 Proteins 0.000 description 1
108091006231 SLC7A2 Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
241000248384 Tetrahymena thermophila Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
241000219793 Trifolium Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
230000009471 action Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
-1 ligations Proteins 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
108010058731 nopaline synthase Proteins 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
108090000446 ribonuclease T(2) Proteins 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
- A01N57/10—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds
- A01N57/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/60—Isolated nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Virology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Dentistry (AREA)
Agronomy & Crop Science (AREA)
Environmental Sciences (AREA)
Pest Control & Pesticides (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)

NO902661A 1987-12-15 1990-06-14 Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer NO308610B1 (no)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
AUPI591187		1987-12-15
AUPI995088		1988-08-19
AUPJ035388		1988-09-09
AUPJ130488		1988-11-04
AUPJ133388		1988-11-07
PCT/AU1988/000478 WO1989005852A1 (en)	1987-12-15	1988-12-14	Ribozymes

Publications (3)

Publication Number	Publication Date
NO902661D0 NO902661D0 (no)	1990-06-14
NO902661L NO902661L (no)	1990-08-14
NO308610B1 true NO308610B1 (no)	2000-10-02

Family

ID=27507391

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO902661A NO308610B1 (no)	1987-12-15	1990-06-14	Ribozymer for anvendelse som midler for behandling av planter, fremgangsmÕte for fremstilling derav, og preparater omfattende slike ribozymer
NO20000369A NO312105B1 (no)	1987-12-15	2000-01-25	Fremgangsmåte for fremstilling av ribozymer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20000369A NO312105B1 (no)	1987-12-15	2000-01-25	Fremgangsmåte for fremstilling av ribozymer

Country Status (19)

Country	Link
EP (2)	EP0321201B2 (de)
JP (1)	JP3046318B2 (de)
KR (1)	KR970010758B1 (de)
CN (1)	CN1102174C (de)
AR (1)	AR243935A1 (de)
AT (1)	ATE115999T1 (de)
AU (1)	AU632993B2 (de)
CA (1)	CA1340831C (de)
DE (1)	DE3852539T3 (de)
DK (1)	DK175956B1 (de)
ES (1)	ES2065919T5 (de)
FI (1)	FI104562B (de)
GR (1)	GR3015374T3 (de)
HU (2)	HUT54407A (de)
MC (1)	MC2115A1 (de)
NO (2)	NO308610B1 (de)
NZ (1)	NZ227332A (de)
RO (1)	RO114469B1 (de)
WO (1)	WO1989005852A1 (de)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5019556A (en) *	1987-04-14	1991-05-28	President And Fellows Of Harvard College	Inhibitors of angiogenin
CA1340323C (en) *	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences
US5866701A (en) *	1988-09-20	1999-02-02	The Board Of Regents For Northern Illinois University Of Dekalb	HIV targeted hairpin ribozymes
US5624824A (en) *	1989-03-24	1997-04-29	Yale University	Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) *	1989-03-24	1992-12-01	Yale University	Cleavage of targeted RNA by RNAase P
DE4091533T (de) *	1989-08-31	1992-01-30
US5225347A (en) *	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Therapeutic ribozyme compositions and expression vectors
US5225337A (en) *	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Ribozyme compositions and methods for use
DE3933384A1 (de) *	1989-10-06	1991-04-18	Hoechst Ag	Multifunktionelle rna mit selbstprozessierungsaktivitaet, ihre herstellung und ihre verwendung
DE3935473A1 (de) *	1989-10-25	1991-05-02	Hoechst Ag	Rna mit endonuclease- und antisense-aktivitaet, ihre herstellung und ihre verwendung
HUT63170A (en) *	1990-01-11	1993-07-28	Isis Pharmaceuticals Inc	Process and composition for detecting and modifying rna activity and gene expression
DE4002885A1 (de) *	1990-02-01	1991-08-08	Hoechst Ag	Expression einer multigen rna mit self-splicing aktivitaet
US5519164A (en) *	1990-02-01	1996-05-21	Hoechst Aktiengesellschaft	Expression of a multigene RNA having self-splicing activity
US5180818A (en) *	1990-03-21	1993-01-19	The University Of Colorado Foundation, Inc.	Site specific cleavage of single-stranded dna
WO1991018913A1 (en) *	1990-06-07	1991-12-12	City Of Hope	Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
AU7152191A (en) *	1990-06-07	1991-12-31	City Of Hope	Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
US6008343A (en) *	1990-06-19	1999-12-28	Gene Shears Pty. Ltd.	Nucleotide based endonucleases
ATE150789T1 (de) *	1990-06-19	1997-04-15	Gene Shears Pty Ltd	Endonukleasen
US5246921A (en) *	1990-06-26	1993-09-21	The Wistar Institute Of Anatomy And Biology	Method for treating leukemias
WO1992000080A1 (en) *	1990-06-26	1992-01-09	The Wistar Institute Of Anatomy & Biology	Method for treating leukemias
JPH06502988A (ja) *	1990-07-26	1994-04-07	ファウンデーション・フォー・リサーチ・アンド・テクノロジー　―　ヘラス（エフオー．アール．ティー．エイチ．）インスティテュート・オブ・モレキュラー・バイオロジー・アンド・バイオテクノロジー	ポータブルリボザイムカセット、それを含有するｄｎａ配列、これらｄｎａ配列によりコードされるリボザイム、およびこれらリボザイムを含有する組成物
WO1992007065A1 (en)	1990-10-12	1992-04-30	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Modified ribozymes
NZ241311A (en) *	1991-01-17	1995-03-28	Gen Hospital Corp	Rna sequence having trans-splicing activity, plant strains
NZ314629A (en) *	1991-01-17	2000-08-25	Gen Hospital Corp	Use trans-splicing ribozymes to prepare medicaments for gene therapies
FR2675803B1 (fr)	1991-04-25	1996-09-06	Genset Sa	Oligonucleotides fermes, antisens et sens et leurs applications.
FI913197A0 (fi)	1991-07-01	1991-07-01	Xyrofin Oy	Nya jaeststammar med reducerad foermaoga att metabolisera xylitol, foerfarande foer bildande av dessa och deras anvaendning vid framstaellning av xylitol.
JPH07502898A (ja) *	1992-01-13	1995-03-30	デューク・ユニバーシティー	酵素ｒｎａ分子
AU656676B2 (en) *	1992-04-17	1995-02-09	Kirin Beer Kabushiki Kaisha	Plant resistant to two or more viruses and preparation thereof
ATE312510T1 (de) *	1992-06-29	2005-12-15	Gene Shears Pty Ltd	Nukleinsäuren und sie verwendende verfahren zur bekämpfung viraler pathogene
US5631115A (en) *	1992-07-02	1997-05-20	Sankyo Company, Limited	Looped, hairpin ribozyme
US5409823A (en) *	1992-09-24	1995-04-25	Ciba-Geigy Corporation	Methods for the production of hybrid seed
US5864028A (en) *	1992-11-03	1999-01-26	Gene Shears Pty. Limited	Degradation resistant mRNA derivatives linked to TNF-α ribozymes
ZA938208B (en) *	1992-11-03	1995-01-03	Gene Shears Pty Ltd	TNF-alpha ribozymes and degradation resistant mRNA derivatives linked to TNF-alpha ribozymes
WO1994013793A1 (en) *	1992-12-04	1994-06-23	Apollon, Inc.	Compounds and methods for the treatment of leukemias
WO1994013791A1 (en) *	1992-12-04	1994-06-23	Innovir Laboratories, Inc.	Regulatable nucleic acid therapeutic and methods of use thereof
JP3595841B2 (ja) *	1992-12-04	2004-12-02	サーナセラピューティクス，インコーポレイテッド	リボザイム増幅診断用薬
FR2701960B1 (fr) *	1993-02-26	2002-09-13	Gene Shears Pty Ltd	Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme.
US5817635A (en) *	1993-08-09	1998-10-06	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Modified ribozymes
AU5334294A (en) *	1993-10-15	1995-05-04	Dkfz Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts	Asymmetric hammerhead ribozymes and nucleotide sequences for their construction
US5869248A (en) *	1994-03-07	1999-02-09	Yale University	Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5998193A (en) *	1994-06-24	1999-12-07	Gene Shears Pty., Ltd.	Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6350934B1 (en)	1994-09-02	2002-02-26	Ribozyme Pharmaceuticals, Inc.	Nucleic acid encoding delta-9 desaturase
US6057153A (en) *	1995-01-13	2000-05-02	Yale University	Stabilized external guide sequences
US5683873A (en) *	1995-01-13	1997-11-04	Innovir Laboratories, Inc.	EGS-mediated inactivation of target RNA
FR2730637B1 (fr)	1995-02-17	1997-03-28	Rhone Poulenc Rorer Sa	Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
EP0837933A4 (de) *	1995-06-07	2003-05-21	Commw Scient Ind Res Org	Optimierte minizyme und miniribozyme und deren anwendungen
US6004806A (en) *	1995-06-07	1999-12-21	Commonwealth Scientific And Industrial Research Organization	Optimized minizymes and miniribozymes and uses thereof
US6010904A (en) *	1995-06-07	2000-01-04	The General Hospital Corporation	Cell ablation using trans-splicing ribozymes
WO1997010328A2 (en) *	1995-07-13	1997-03-20	Ribozyme Pharmaceuticals, Inc.	Compositions and method for modulation of gene expression in plants
US5824519A (en) *	1995-11-08	1998-10-20	Medical University Of South Carolina	Tissue-specific and target RNA-specific ribozymes
US5877162A (en) *	1996-03-14	1999-03-02	Innovir Laboratories, Inc.	Short external guide sequences
US6620805B1 (en)	1996-03-14	2003-09-16	Yale University	Delivery of nucleic acids by porphyrins
US5976874A (en) *	1996-08-16	1999-11-02	Yale University	Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6610478B1 (en)	1996-08-16	2003-08-26	Yale University	Phenotypic conversion of cells mediated by external guide sequences
US6884430B1 (en)	1997-02-10	2005-04-26	Aventis Pharma S.A.	Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
US6969601B2 (en)	1997-04-03	2005-11-29	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
US7589253B2 (en)	1997-04-15	2009-09-15	Commonwealth Scientific And Industrial Research Organisation	Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism
PL194095B1 (pl)	1997-04-15	2007-04-30	Commw Scient Ind Res Org	Wyizolowana cząsteczka kwasu nukleinowego, konstrukt genetyczny, sposób dokonywania zmian poziomu epoksykwasów tłuszczowych, sposób wytwarzania rekombinantowego polipeptydu monooksygenazy w komórce, sposób wytwarzania rekombinantowego polipeptydu monooksygenazy w roślinie transgenicznej, polipeptydrekombinantowy, sposób wytwarzania epoksydowanegokwasu tłuszczowego, roślina transformowana i roślina lub pochodząca z niej komórka
DE69826124T3 (de)	1997-06-30	2007-10-11	Institut Gustave Roussy	Verabreichung der nukleinsäure in den quergestreiften muskel
JP2001516582A (ja)	1997-09-16	2001-10-02	クロップデザインエヌ．ブイ．	サイクリン依存性キナーゼ阻害物質およびその使用
DE19741375C2 (de) *	1997-09-19	1999-10-21	Max Planck Gesellschaft	Transgene Pflanzen, deren oberirdische Teile früher reifen und vollständig absterben
WO1999017798A1 (en)	1997-10-02	1999-04-15	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
JP4749541B2 (ja)	1997-11-18	2011-08-17	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	レスポンダー表現型に関わる核酸およびその適用
US6013447A (en) *	1997-11-21	2000-01-11	Innovir Laboratories, Inc.	Random intracellular method for obtaining optimally active nucleic acid molecules
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt)	1998-03-20	2017-05-30	Benitec Australia Ltd	processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
US6248525B1 (en)	1998-03-30	2001-06-19	Yale University	Method for identifying essential or functional genes
AU4830899A (en)	1998-06-24	2000-01-10	Musc Foundation For Research Development	Tissue-specific and target rna-specific ribozymes
DE19836098A1 (de)	1998-07-31	2000-02-03	Hoechst Schering Agrevo Gmbh	Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke
JP2002527066A (ja)	1998-10-15	2002-08-27	カイロンコーポレイション	転移性乳癌および結腸癌調節遺伝子
CN100408687C (zh) *	1998-11-09	2008-08-06	拜尔生物科学有限公司	来自稻米的核酸分子及其用于生产改性淀粉的用途
TR200101342T2 (tr)	1998-11-12	2001-09-21	Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften	Patojen enfeksiyonu üzerine bitkilerde gen ekspresyonuna aracılık edebilen şimerik promoterler
EP1961813B1 (de)	1998-12-16	2011-08-10	Novartis Vaccines and Diagnostics, Inc.	Menschliche Cyclin-abhängige Kinase (hPNQALRE)
US6271359B1 (en)	1999-04-14	2001-08-07	Musc Foundation For Research Development	Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2365901A1 (en)	1999-04-14	2000-10-19	Musc Foundation For Research Development	Tissue-specific and pathogen-specific toxic agents and ribozymes
AUPQ005299A0 (en)	1999-04-29	1999-05-27	Commonwealth Scientific And Industrial Research Organisation	Novel genes encoding wheat starch synthases and uses therefor
ATE305718T1 (de)	1999-07-20	2005-10-15	Gvs Ges Fuer Erwerb Und Verwer	Neues verfahren zur herstellung und auswahl von transgenen flachspflanzen und leinsamen
US6423885B1 (en)	1999-08-13	2002-07-23	Commonwealth Scientific And Industrial Research Organization (Csiro)	Methods for obtaining modified phenotypes in plant cells
JP5610659B2 (ja)	2000-07-21	2014-10-22	ルバンスセラピュティックスインク．ＲｅｖａｎｃｅＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	多成分生物学的輸送システム
CN1482856A (zh)	2000-11-09	2004-03-17	��Ƽ��ҵ�о��֯	降低了ssii活性的大麦和降低了支链淀粉含量的淀粉和淀粉制品
ITMI20011364A1 (it) *	2001-06-28	2002-12-28	Metapontum Agrobios S C R L	Robozima hammerhead specifico per la stearoyl-acp desaturesi di piante oleaginose differenti
US7994144B2 (en)	2001-07-10	2011-08-09	Johnson & Johnson Research Pty, Limited	Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CN1553963A (zh)	2001-07-10	2004-12-08	ǿ��ǿ��о��޹�˾	用于遗传修饰造血祖细胞的方法和这些被修饰细胞的应用
US8022272B2 (en)	2001-07-13	2011-09-20	Sungene Gmbh & Co. Kgaa	Expression cassettes for transgenic expression of nucleic acids
FR2829136B1 (fr)	2001-08-29	2006-11-17	Aventis Pharma Sa	Derives lipidiques d'aminoglycosides
US7456335B2 (en)	2001-09-03	2008-11-25	Basf Plant Science Gmbh	Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
EP2284195A1 (de)	2001-09-18	2011-02-16	Carnegie Institution Of Washington	Fusionsproteine zur Detektion von Analyten
AU2002359761A1 (en)	2001-12-18	2003-06-30	Invenux, Inc.	Antibiotic compounds
US7432371B2 (en)	2002-02-07	2008-10-07	Covalent Partners, Llc	Nanofilm and membrane compositions
US20040005546A1 (en)	2002-02-28	2004-01-08	Oncolytics Biotech Inc.	Use of ribozymes in the detection of adventitious agents
DE10212892A1 (de)	2002-03-20	2003-10-09	Basf Plant Science Gmbh	Konstrukte und Verfahren zur Regulation der Genexpression
EP1365034A3 (de)	2002-05-21	2004-02-18	Bayer HealthCare AG	Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
US7771952B2 (en)	2002-06-26	2010-08-10	Abott Laboratories	Modulators and modulation of the interaction between RGM and Neogenin
ATE546539T1 (de)	2002-07-26	2012-03-15	Basf Plant Science Gmbh	Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
EP2258724A1 (de)	2002-11-21	2010-12-08	Celltech R & D, Inc.	Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
DE60323149D1 (de)	2002-12-19	2008-10-02	Bayer Cropscience Gmbh	Pflanzenzellen und pflanzen, die eine stärke mit erhöhter endviskosität synthetisieren
CN1798769A (zh)	2003-05-12	2006-07-05	内蒂穆恩公司	抗masp－2抗体
WO2005001098A1 (en)	2003-06-30	2005-01-06	Commonwealth Scientific And Industrial Research Organisation	Wheat with altered branching enzyme activity and starch and starch containing products derived thereform
EP1892306A3 (de)	2003-10-06	2008-06-11	Bayer HealthCare AG	Verfahren und Kit zur Untersuchung von Krebs
EP1602926A1 (de)	2004-06-04	2005-12-07	University of Geneva	Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7604947B2 (en)	2004-06-09	2009-10-20	Cornell Research Foundation, Inc.	Detection and modulation of cancer stem cells
EP2386315A1 (de)	2004-06-10	2011-11-16	Omeros Corporation	Verfahren zur Behandlung von Leiden in Zusammenhang mit MASP-2-abhängiger Komplementaktivierung
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
EP1763582B1 (de)	2004-07-08	2014-12-10	DLF - Trifolium A/S	Mittel und Verfahren zur Steuerung der Blüte in Pflanzen
EP1781784A2 (de)	2004-08-02	2007-05-09	BASF Plant Science GmbH	Verfahren zur isolierung von transkriptionsterminationssequenzen
AU2005286427B2 (en)	2004-09-24	2011-09-15	Basf Plant Science Gmbh	Plant cells and plants with increased tolerance to environmental stress
WO2006069422A1 (en)	2004-12-30	2006-07-06	Commonwealth Scientific And Industrial Research Organisation	Method and means for improving bowel health
EP1707632A1 (de)	2005-04-01	2006-10-04	Bayer CropScience GmbH	Phosphorylierte waxy-Kartoffelstärke
CN101277974A (zh)	2005-09-30	2008-10-01	阿伯特有限及两合公司	排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
CA2628505A1 (en)	2005-11-08	2007-05-18	Basf Plant Science Gmbh	Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
CA2632872A1 (en)	2006-01-12	2007-07-19	Basf Plant Science Gmbh	Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
CA2644273A1 (en)	2006-04-05	2008-03-27	Metanomics Gmbh	Process for the production of a fine chemical
EP2030021B1 (de)	2006-05-18	2012-11-21	Andreas Reichert	Verfahren zur diagnose mitochondrialer fehlfunktion
US8383597B2 (en)	2006-05-25	2013-02-26	Cornell Research Foundation, Inc.	G proteins in tumor growth and angiogenesis
US9127311B2 (en)	2006-10-06	2015-09-08	Speedx Pty Ltd	Molecular switches and methods for their use
DK2202314T3 (da)	2007-01-15	2014-06-16	Basf Plant Science Gmbh	Anvendelse af subtilisin (RNR9)-polynukleotider til opnåelse af patogenresistens i planter
CA2675926A1 (en)	2007-02-16	2008-08-21	Basf Plant Science Gmbh	Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
WO2008119057A2 (en)	2007-03-27	2008-10-02	Omeros Corporation	The use of pde7 inhibitors for the treatment of movement disorders
US20100162432A1 (en)	2007-05-22	2010-06-24	Basf Plant Science Gmbh	Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2040075A1 (de)	2007-09-24	2009-03-25	Julius-Maximilians-Universität Würzburg	Verbindungen und Marker für oberflächenverstärkte Raman-Streuung
JP2011506483A (ja)	2007-12-14	2011-03-03	アムジエン・インコーポレーテツド	抗スクレロスチン抗体を用いた骨折の治療方法
US20100293665A1 (en)	2007-12-21	2010-11-18	Basf Plant Science Gmbh	Plants With Increased Yield (KO NUE)
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
EP2100962A1 (de)	2008-03-12	2009-09-16	Biogemma	Pflanzen mit verbesserter Widerstandsfähigkeit gegen Pathogene
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
WO2010026537A1 (en)	2008-09-05	2010-03-11	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Novel multimodular assembly useful for intracellular delivery
EP2184351A1 (de)	2008-10-30	2010-05-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Polynukleotid-kondierende Caryophyllen-Synthase und ihre Verwendung
ES2363358B1 (es)	2009-04-03	2012-06-21	FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al	Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
CA3020943A1 (en)	2009-04-22	2010-10-28	Basf Plant Science Company Gmbh	Whole seed specific promoter
EP2475367A1 (de)	2009-09-10	2012-07-18	Centre National De La Recherche Scientifique	Neuartige stearoyl-coa-desaturase-1-hemmer und ihre verwendung
EP2305285A1 (de)	2009-09-29	2011-04-06	Julius-Maximilians-Universität Würzburg	Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
AU2010306581B2 (en)	2009-10-16	2015-03-19	Omeros Corporation	Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
WO2011051478A1 (en)	2009-10-30	2011-05-05	Domain Therapeutics	Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP2322149A1 (de)	2009-11-03	2011-05-18	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Ischämie
KR20120118002A (ko)	2009-12-08	2012-10-25	애보트 게엠베하 운트 콤파니 카게	망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍａ 단백질에 대한 모노클로날 항체
EP2338492A1 (de)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Alzheimer
US8476485B2 (en)	2010-06-24	2013-07-02	Academia Sinica	Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
KR20130124333A (ko)	2010-11-08	2013-11-13	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US9644035B2 (en)	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
CN107638565B (zh)	2011-04-08	2021-12-21	莱斯特大学	用于治疗与masp-2依赖性补体活化相关的状况的方法
WO2013066438A2 (en)	2011-07-22	2013-05-10	President And Fellows Of Harvard College	Evaluation and improvement of nuclease cleavage specificity
WO2013025936A1 (en)	2011-08-18	2013-02-21	Cornell University	Detection and treatment of metastatic disease
WO2013039880A1 (en)	2011-09-12	2013-03-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Biomarkers and therapeutic targets of hepatocellular cancer
CA2859564C (en)	2011-12-16	2020-04-14	Board Of Trustees Of Michigan State University	P-coumaroyl-coa:monolignol transferase
EP3369746A1 (de)	2012-01-27	2018-09-05	AbbVie Deutschland GmbH & Co KG	Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
WO2013138456A1 (en)	2012-03-14	2013-09-19	University Of Central Florida Research Foundation, Inc.	Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
EP2666775A1 (de)	2012-05-21	2013-11-27	Domain Therapeutics	Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
WO2014127835A1 (en)	2013-02-22	2014-08-28	Christian-Albrechts-Universität Zu Kiel	Plant-derived resistance gene
US20150044192A1 (en)	2013-08-09	2015-02-12	President And Fellows Of Harvard College	Methods for identifying a target site of a cas9 nuclease
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
US9388430B2 (en)	2013-09-06	2016-07-12	President And Fellows Of Harvard College	Cas9-recombinase fusion proteins and uses thereof
RS61351B1 (sr)	2013-10-17	2021-02-26	Omeros Corp	Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US20150166984A1 (en)	2013-12-12	2015-06-18	President And Fellows Of Harvard College	Methods for correcting alpha-antitrypsin point mutations
PE20170253A1 (es)	2013-12-18	2017-04-14	Nuseed Pty Ltd	Lipido que comprende acidos grasos poliinsaturados de cadena larga
AU2015281791A1 (en)	2014-06-27	2017-01-12	Commonwealth Scientific And Industrial Research Organisation	Lipid comprising docosapentaenoic acid
WO2016022363A2 (en)	2014-07-30	2016-02-11	President And Fellows Of Harvard College	Cas9 proteins including ligand-dependent inteins
EP3000814A1 (de)	2014-09-26	2016-03-30	Domain Therapeutics	Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
SG10202104041PA (en)	2015-10-23	2021-06-29	Harvard College	Nucleobase editors and uses thereof
EA201891132A1 (ru)	2015-11-09	2018-10-31	Омерос Корпорейшн	Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
SG11201805695SA (en)	2016-01-05	2018-07-30	Univ Leicester	Methods for inhibiting fibrosis in a subject in need thereof
EA202191185A1 (ru)	2016-03-31	2021-10-29	Омерос Корпорейшн	Способы ингибирования ангиогенеза у пациента
WO2017202715A1 (en)	2016-05-26	2017-11-30	Nunhems B.V.	Seedless fruit producing plants
KR20250103795A (ko)	2016-08-03	2025-07-07	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en)	2016-08-09	2023-05-30	President And Fellows Of Harvard College	Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en)	2016-08-24	2018-03-01	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
FI3565891T3 (fi)	2017-01-09	2023-07-04	Whitehead Inst Biomedical Res	Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
EP3592381A1 (de)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Krebsimpfstoff
WO2018165629A1 (en)	2017-03-10	2018-09-13	President And Fellows Of Harvard College	Cytosine to guanine base editor
US10883089B2 (en)	2017-04-04	2021-01-05	Wisconsin Alumni Research Foundation	Feruloyl-CoA:monolignol transferases
US10883090B2 (en)	2017-04-18	2021-01-05	Wisconsin Alumni Research Foundation	P-coumaroyl-CoA:monolignol transferases
JP7598137B2 (ja)	2017-07-17	2024-12-11	ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト	放射線または放射線療法によって引き起こされた放射線誘発性バイスタンダ効果を防止および治療するための組成物および方法
CN111801345A (zh)	2017-07-28	2020-10-20	哈佛大学的校长及成员们	使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
TW202529812A (zh)	2017-08-15	2025-08-01	美商歐米諾斯公司	用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
EP3676376B1 (de)	2017-08-30	2025-01-15	President and Fellows of Harvard College	Hocheffiziente baseneditoren mit gam
US11795443B2 (en)	2017-10-16	2023-10-24	The Broad Institute, Inc.	Uses of adenosine base editors
WO2019118949A1 (en)	2017-12-15	2019-06-20	The Broad Institute, Inc.	Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en)	2018-05-23	2024-12-03	The Broad Institute, Inc.	Base editors and uses thereof
CN118373875A (zh)	2018-05-29	2024-07-23	奥默罗斯公司	Masp-2抑制剂和使用方法
US11584714B2 (en)	2018-05-29	2023-02-21	Omeros Corporation	MASP-2 inhibitors and methods of use
US11291176B2 (en)	2018-06-15	2022-04-05	Nunhems B.V.	Seedless watermelon plants comprising modifications in an ABC transporter gene
EP3820495A4 (de)	2018-07-09	2022-07-20	The Broad Institute Inc.	Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
WO2020092453A1 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Nucleobase editors comprising geocas9 and uses thereof
US11981904B2 (en)	2018-11-09	2024-05-14	Wisconsin Alumni Research Foundation	BAHD acyltransferases
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
EP3942043A2 (de)	2019-03-19	2022-01-26	The Broad Institute, Inc.	Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
WO2020214842A1 (en)	2019-04-17	2020-10-22	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
KR20220110531A (ko)	2019-12-04	2022-08-08	오메로스 코포레이션	Masp-2 억제자 및 사용 방법
WO2021113698A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
WO2021113682A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
TWI867422B (zh)	2020-03-06	2024-12-21	美商奥默羅斯公司	用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
BR112022022603A2 (pt)	2020-05-08	2023-01-17	Broad Inst Inc	Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN116096378A (zh)	2020-08-10	2023-05-09	诺华股份有限公司	视网膜变性疾病的治疗
AU2023326563A1 (en)	2022-08-18	2025-02-27	Mitodicure Gmbh	Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
CN119923254A (zh)	2022-08-26	2025-05-02	米托迪治愈有限责任公司	具有钠氢反向转运物1抑制活性的治疗剂用于治疗和预防与慢性疲劳、筋疲力尽和/或劳累不耐受相关的疾病的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4987071A (en) *	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) *	1986-12-03	1992-05-26	University Patents, Inc.	RNA ribozyme restriction endoribonucleases and methods
DE3642623A1 (de) *	1986-12-13	1988-06-23	Burbach & Bender Ohg	Gasspuelstein fuer metallurgische gefaesse
DE3939771A1 (de) *	1989-12-01	1991-06-06	Behringwerke Ag	Verfahren zur biologischen inaktivierung von nukleinsaeuren

1988
- 1988-12-14 AU AU28007/89A patent/AU632993B2/en not_active Expired
- 1988-12-14 AR AR88312737A patent/AR243935A1/es active
- 1988-12-14 EP EP88311816A patent/EP0321201B2/de not_active Expired - Lifetime
- 1988-12-14 DE DE3852539T patent/DE3852539T3/de not_active Expired - Lifetime
- 1988-12-14 CA CA000585845A patent/CA1340831C/en not_active Expired - Fee Related
- 1988-12-14 NZ NZ227332A patent/NZ227332A/xx unknown
- 1988-12-14 JP JP1500279A patent/JP3046318B2/ja not_active Expired - Lifetime
- 1988-12-14 RO RO145344A patent/RO114469B1/ro unknown
- 1988-12-14 MC MC882115D patent/MC2115A1/xx unknown
- 1988-12-14 EP EP94107862A patent/EP0640688A1/de not_active Withdrawn
- 1988-12-14 ES ES88311816T patent/ES2065919T5/es not_active Expired - Lifetime
- 1988-12-14 WO PCT/AU1988/000478 patent/WO1989005852A1/en not_active Ceased
- 1988-12-14 HU HU89382A patent/HUT54407A/hu unknown
- 1988-12-14 KR KR1019890701528A patent/KR970010758B1/ko not_active Expired - Fee Related
- 1988-12-14 AT AT88311816T patent/ATE115999T1/de not_active IP Right Cessation
- 1988-12-15 CN CN88108572A patent/CN1102174C/zh not_active Expired - Lifetime
1990
- 1990-06-12 DK DK199001433A patent/DK175956B1/da not_active IP Right Cessation
- 1990-06-12 FI FI902923A patent/FI104562B/fi not_active IP Right Cessation
- 1990-06-14 NO NO902661A patent/NO308610B1/no unknown
1995
- 1995-03-13 GR GR940403895T patent/GR3015374T3/el unknown
- 1995-06-22 HU HU95P/P00362P patent/HU211891A9/hu unknown
2000
- 2000-01-25 NO NO20000369A patent/NO312105B1/no unknown

Also Published As

Publication number	Publication date
JP3046318B2 (ja)	2000-05-29
DK143390D0 (da)	1990-06-12
DK175956B1 (da)	2005-08-22
AU632993B2 (en)	1993-01-21
NO902661L (no)	1990-08-14
AU2800789A (en)	1989-07-19
CA1340831C (en)	1999-11-30
WO1989005852A1 (en)	1989-06-29
ES2065919T5 (es)	2005-06-16
AR243935A1 (es)	1993-09-30
JPH03502638A (ja)	1991-06-20
ES2065919T3 (es)	1995-03-01
FI902923A0 (fi)	1990-06-12
EP0640688A1 (de)	1995-03-01
ATE115999T1 (de)	1995-01-15
FI104562B (fi)	2000-02-29
NO312105B1 (no)	2002-03-18
HU211891A9 (en)	1995-12-28
DE3852539D1 (de)	1995-02-02
NZ227332A (en)	1991-08-27
DK143390A (da)	1990-08-14
GR3015374T3 (en)	1995-06-30
CN1102174C (zh)	2003-02-26
DE3852539T3 (de)	2005-08-04
DE3852539T2 (de)	1995-05-04
NO20000369D0 (no)	2000-01-25
KR970010758B1 (ko)	1997-06-30
EP0321201B2 (de)	2004-11-24
EP0321201A3 (en)	1990-01-10
KR900700603A (ko)	1990-08-16
EP0321201A2 (de)	1989-06-21
NO902661D0 (no)	1990-06-14
EP0321201B1 (de)	1994-12-21
HUT54407A (en)	1991-02-28
NO20000369L (no)	1990-08-14
RO114469B1 (ro)	1999-04-30
CN1033838A (zh)	1989-07-12
MC2115A1 (fr)	1991-07-05

Publication	Publication Date	Title
NO312105B1 (no)	2002-03-18	Fremgangsmåte for fremstilling av ribozymer
US5254678A (en)	1993-10-19	Ribozymes
US5543508A (en)	1996-08-06	Ribozymes
Steinecke et al.	1992	Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo.
US5874414A (en)	1999-02-23	Trans-splicing ribozymes
IE920125A1 (en)	1992-07-29	Cell ablation using trans-splicing ribozymes
AU2707295A (en)	1996-01-19	Ribozymes with optimized hybridizing arms, stems, and loops,tRNA embedded ribozymes and compositions thereof
RU2144080C1 (ru)	2000-01-10	Рибозим, способ инактивации рнк-мишени, способ получения рибозима
Tabler	1993	Antisense RNA in plants: A tool for analysis and suppression of gene function
Liu et al.	2000	Episomal expression of a hammerhead ribozyme directed against plum pox virus
IL88683A (en)	1995-11-27	Ribozymes their production and pharmaceutical compositions containing them
AU653787C (en)	1998-01-08	Cell ablation using trans-splicing ribozymes
Friday	2017	Processing of Potato Spindle Tuber Viroids (PSTVd) RNAs in Yeast, a Nonconventional Host